Novanta Inc. — Q3 2022 Form 10-Q
Reporting period: Quarter and nine months ended September 30, 2022; comparisons are with the three and nine months ended October 1, 2021. Figures are in U.S. dollars unless otherwise noted. Novanta supplies photonics, vision, and precision-motion technologies to medical and advanced-industrial OEMs.
Financial performance
| Metric | Q3 2022 | Q3 2021 | Nine months 2022 | Nine months 2021 |
|---|---|---|---|---|
| Revenue | $223.0 million | $177.7 million | $642.5 million | $507.8 million |
| Gross profit | $98.4 million | $76.3 million | $283.9 million | $217.4 million |
| Gross margin | 44.1% | 42.9% | 44.2% | 42.8% |
| Operating income | $28.7 million | $15.3 million | $76.2 million | $42.4 million |
| Net income | $22.5 million | $13.6 million | $58.8 million | $36.6 million |
| Diluted EPS | $0.63 | $0.38 | $1.64 | $1.02 |
| Operating cash flow | Not provided for quarter | Not provided for quarter | $50.2 million | $65.9 million |
- Q3 revenue increased 25.5%; nine-month revenue rose 26.5%. Prior-year acquisitions contributed $22.3 million in Q3 and $90.1 million for the nine-month period. Foreign exchange reduced revenue by $13.7 million and $25.6 million, respectively.
- Q3 growth spanned all segments: Photonics revenue rose 28.1%, Vision 12.2%, and Precision Motion 38.0%. Nine-month growth was led by Precision Motion, up 76.3%, including $88.0 million of 2021 acquisition revenue. Vision’s nine-month increase was 2.3%, with supply constraints a partial offset.
- Consolidated gross margin improved year over year in both comparisons. Q3 Photonics margin improved to 49.0% from 45.8%, while Precision Motion declined to 46.7% from 48.6%. For nine months, Photonics margin fell to 46.4% from 47.1%; management cited supply disruption and raw-material inflation. Precision Motion cited those pressures and unfavorable mix for its Q3 margin decline.
- Operating income growth reflected higher gross profit and lower restructuring/acquisition costs, partly offset by higher R&D, SG&A, and acquired-intangible amortization. Nine-month interest expense increased to $9.9 million from $4.5 million; the senior-facility weighted average rate was 2.72% versus 2.12%.
Liquidity, debt, and capital allocation
- At September 30, cash and cash equivalents were $84.6 million, down from $117.4 million at year-end 2021. Current assets were $407.7 million and current liabilities $158.1 million.
- Gross borrowings under senior credit facilities were $442.8 million, including $372.3 million drawn on the revolver and $75.7 million of term-loan principal. The company reported $322.7 million of unused and available revolver capacity. Debt matures March 10, 2027 following a March 2022 amendment that also replaced LIBOR with SOFR.
- The company reported compliance with its credit covenants: leverage ratio 2.33 against a 3.50 maximum, and fixed-charge coverage 8.89 against a 1.50 minimum. Substantially all company assets secure the facilities.
- Nine-month operating cash flow declined to $50.2 million, principally reflecting higher inventory and accounts receivable, and a bonus payout. Inventory was $162.8 million versus $125.7 million at year-end; receivables were $144.6 million versus $115.6 million.
- Nine-month investing cash outflow was $38.3 million, including the MPH acquisition and $15.4 million of capital expenditures. Financing cash outflow was $36.7 million, including $45.0 million paid for ATI acquisition contingent consideration, debt repayments, and $10.0 million of share repurchases. Management expected 2022 capital expenditures of approximately $20 million to $25 million.
Outlook, commentary, and risks
- No specific revenue or earnings guidance is stated in the provided filing text. Management said operating cash flows should fund operating and capital needs for at least the next 12 months, while noting liquidity is exposed to business and market risks.
- Novanta acquired Czech medical-consumables maker MPH for approximately $22.4 million net of cash, financed with cash and revolver borrowings. MPH contributed $2.1 million of revenue and $0.2 million of pretax profit in the nine-month period; its purchase-price allocation remained preliminary.
- A new 2022 restructuring program began in Q3 to reduce operating complexity and improve costs and margins. The company expected to complete it substantially by year-end 2023 and incur a further $5 million to $6 million in charges. It also expected another $1.5 million to $2.0 million of charges under its 2020 program, which it anticipated completing substantially in Q1 2023.
- Management described ongoing supply-chain constraints, electronics and raw-material shortages, transportation delays, and inflation in materials, labor, freight, and other inputs. Pricing and productivity actions had offset some cost increases, but recovery was not assured. China lockdowns had limited operational impact through the period; future effects were uncertain. Russia sales were not material, but broader conflict and sanctions effects remained uncertain.
- The 2022 tax rules requiring capitalization and amortization of R&D expenditures increased cash taxes and deferred tax assets. Management estimated a potential $9.2 million reduction in 2022 operating cash flow if the provision was not changed retroactively. Management’s initial assessment was that the Inflation Reduction Act would not materially affect income tax provision or cash taxes.
- Legal proceedings arise in the ordinary course; the company did not believe their outcomes would materially adversely affect results, but gave no quantified exposure. Management reported disclosure controls were effective and no material change in internal control during the quarter.
Important facts for investors to verify
- How much reported growth reflects acquisitions, underlying demand, and foreign-exchange movements, particularly in Precision Motion.
- Whether inventory and receivables convert to cash and whether operating cash flow recovers from the nine-month decline.
- The effects of supply constraints, input-cost inflation, product mix, and pricing on segment margins.
- Debt cost and covenant headroom as interest rates and borrowings change; confirm availability of the stated revolver capacity and accordion option.
- Final valuation and integration performance of MPH, plus actual costs, timing, and savings from the 2020 and 2022 restructuring programs.
- Whether the expected R&D-related cash-tax impact occurs and whether tax-law changes alter the estimate.